CD133, a pentaspan transmembrane protein, has been used by several groups to identify cancer stem cells in colorectal cancer [25, 26] and Pohl et al. [27] suggested that CD133 might be a predictive marker for standard first-line bevacizumab-based treatment in mCRC. This evidence concerns the gene PROM1 and cancer.